Connect Biopharma's Rademikibart Cuts Asthma Treatment Failure by 66% in Phase 2
CNTB is trading near its 52-week low of $1.23 (24% below the low) on elevated volume (3.8× avg).
Summary
Connect Biopharma reported positive preliminary topline Phase 2 data for rademikibart in acute asthma exacerbations. The drug reduced 28-day treatment failure by 66% versus placebo and showed statistically significant FEV1 improvement at Day 7. The company plans to engage the FDA on Phase 3 design, with COPD Phase 2 data expected later this month. This is a meaningful clinical milestone for a micro-cap biotech trading near its 52-week low, and the data supports advancement toward registrational studies. The upcoming COPD readout is the next key event to watch.
At the time of this announcement, CNTB was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.6M. The 52-week trading range was $1.23 to $3.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.